A specific hormonal medicine, not a supplement
Gonadorelin reproduces the GnRH signal, but its name alone does not tell you what a product does or who it is intended for. In France, LUTRELEF is indicated for ovulation induction in certain forms of infertility of hypothalamic origin. This framework does not validate using it on your own to increase testosterone, libido or performance.
The HAS opinion on LUTRELEF concerns a specific medicinal product and indication. It does not apply to every vial bearing the word “gonadorelin”. A research product and a veterinary medicine are not cheaper substitutes for this prescription.
Official sources were consulted on 13 October 2026. This analysis helps you understand the identities, limitations and questions to ask your specialist. It provides no dosage, reconstitution instructions, self-injection schedule or purchase link. No personal testing is claimed.
Gonadorelin and GnRH: where does the signal act?
GnRH stands for gonadotropin-releasing hormone, the hormone that triggers gonadotropin release. LHRH is another historical name for this signal. Gonadorelin is a synthetic peptide that reproduces the natural molecule. The LHRH FERRING Summary of Product Characteristics (SmPC) describes its action on the release of LH and FSH by the pituitary gland.
The following diagram shows the levels of action:
Hormonal identities
The hypothalamic–pituitary–gonadal axis
- HypothalamusGnRH signal. Gonadorelin reproduces this hormone.
- Pituitary glandRelease of LH and FSH, the gonadotropins.
- Ovaries or testesReproductive and hormonal response depending on the organ and how it functions.
Gonadorelin and gonadotropins are therefore not synonyms. Confusing the messenger sent to the pituitary gland with the hormones sent to the gonads means confusing two steps. The European guidelines on male infertility distinguish, among other things, FSH, hCG and pulsatile GnRH in different treatment approaches. hCG has LH-like activity, but it is not gonadorelin.
This distinction prevents a common mistake: believing that a drug acting further “upstream” is necessarily more natural, more comprehensive or safer. The right level of intervention depends on the diagnosis, not its position in a diagram.
Why pulsatile stimulation matters
Hormonal stimulation is defined by the molecule and its exposure profile. Pulsatile treatment aims to reproduce pulses, using an appropriate device and monitoring. The study by Quaas and colleagues, published in 2022, specifically examines pulsatile administration in women with functional hypothalamic amenorrhoea who wanted to conceive.
By contrast, the SmPC for GONAPEPTYL, containing triptorelin, describes initial stimulation followed, as treatment continues, by a decrease in LH, FSH and sex hormones. Acting on the same receptor can therefore lead to a different final effect.
A hormone spike is not a treatment plan. The amount stated on a vial tells you neither the stimulation profile nor the pituitary gland’s ability to respond. A schedule found on a forum does not become pulsatile in the medical sense just because it includes several injections.
LUTRELEF: French indications and relevant populations
The indication assessed by HAS is ovulation induction in anovulation of hypothalamic origin: class I and class IIa of the classification cited in the document, the latter after clomiphene citrate has failed. This wording does not mean “any menstrual cycle disorder” or “any infertility”.
An absence of periods does not, on its own, identify the mechanism. The Endocrine Society guidelines on functional hypothalamic amenorrhoea define it as a diagnosis of exclusion. They recommend, among other things, checking for pregnancy and other possible causes, and correcting an energy imbalance where present. Treatment aimed at achieving pregnancy does not replace this care.
For a patient wishing to conceive, these guidelines suggest pulsatile GnRH after a complete fertility assessment, with a low level of evidence for this recommendation. An established regulatory indication and high certainty across all comparisons of effectiveness are two different things.
What a human study shows, and its limitation
Quaas’s single-centre retrospective cohort included 66 patients, with 82 treatments and 212 cycles between 1996 and 2020. The authors report a 65.9% live birth rate per treatment, not per injection or per cycle. Several cycles could belong to the same treatment.
This result concerns selected patients monitored at a specialist centre. It does not predict your chance of pregnancy and proves no benefit for a healthy adult seeking a “boost”. The control group was used to compare newborn birth weights, not to establish the treatment’s superiority through randomisation. Two authors declared consulting or speaking activities for Ferring, with no industry support declared for the study.
In its 2015 opinion, HAS also noted major biases in a small comparative trial. My takeaway is targeted clinical usefulness, without turning these data into a universal ranking of fertility treatments.
Table: human medicine, analogue, veterinary product or research product
The table uses identifiable medicinal products rather than a vague category of “hormonal peptides”. The indications for analogues depend on the specific product and its formulation.
Here are the main verified distinctions:
| Identity | Action or use | Relevant population | Documented French status |
|---|---|---|---|
| LUTRELEF, gonadorelin acetate | Ovulation induction in the hypothalamic context described above | Patients with the corresponding fertility indication | Human medicine, valid marketing authorisation, List I |
| LHRH FERRING, gonadorelin acetate | Diagnostic assessment of gonadotropic function | Children, adolescents or adults depending on the clinical situation | Human medicine, valid marketing authorisation, List I, diagnostic use only |
| GONAPEPTYL, prolonged-release triptorelin | GnRH agonist, hormonal suppression after initial stimulation | Certain prostate, gynaecological or precocious puberty indications | Prescription human medicinal product, product-specific SmPC |
| GANIRELIX THERAMEX, ganirelix | GnRH antagonist, prevention of premature LH surges in assisted reproduction | Patients undergoing controlled ovarian stimulation | Human medicine prescribed by an infertility specialist |
| CYSTORELINE, gonadorelin as diacetate tetrahydrate | Veterinary reproductive uses | Cattle and rabbits | French veterinary marketing authorisation, prescription-only |
| Vial described as a research product | Identity and intended use declared by the seller | No human use established by this label alone | No equivalence to an authorised medicinal product demonstrated by the word “research” |
The corresponding sources are the official product records for LUTRELEF, LHRH FERRING, GONAPEPTYL, GANIRELIX THERAMEX and CYSTORELINE.
Analogues are not interchangeable copies
With long-acting triptorelin, the aim may be to reduce sex hormones. With ganirelix, the SmPC describes rapid competitive blockade, without the initial stimulation caused by agonists. The term “GnRH” therefore covers strategies that do not pursue the same goal.
The veterinary SmPC for Cystoreline covers, among other things, ovulation in cows and female rabbits, as well as reproductive disorders or programmes specific to cattle. Its authorisation is not a human authorisation. Species, formulation and indications are not details you can convert with a simple proportional calculation.
Testosterone and biohacking: extrapolations to avoid
Stimulating LH and FSH can make sense in an identified disease. This does not demonstrate that someone with fatigue or low libido needs gonadorelin. The Endocrine Society requires compatible symptoms and consistently low testosterone concentrations, confirmed by repeat morning blood sampling, to diagnose male hypogonadism. LH and FSH help distinguish a testicular origin from a hypothalamic–pituitary origin.
There are specialist uses of pulsatile GnRH in certain forms of hypogonadism associated with male infertility, mentioned by the EAU. This does not create a “testosterone optimisation” indication for LUTRELEF in France. A medical option for a population with a disease does not validate wellness use.
An increase in LH after a test is not evidence of lasting benefits for desire, fertility, strength or energy. The test aims to obtain diagnostic information. Selling it as an “axis reboot” changes the goal without providing the missing evidence.
The kisspeptin trials on libido · FR concern yet another intervention. Their results cannot be transferred to gonadorelin. Peptides linked to the same hormonal axis do not automatically share indications or clinical effects.
Risks and precautions: what requires monitoring
The LUTRELEF SmPC lists, among other contraindications, hypersensitivity, hormone-dependent tumours, pituitary adenomas, certain ovarian abnormalities and non-hypothalamic anovulation. It describes local reactions, allergies and a risk of ovarian hyperstimulation, which is uncommon with pulsatile administration. Multiple pregnancies and miscarriages are also among the risks discussed in ovulation induction.
Monitoring is therefore not just about confirming ovulation. It is also about identifying an excessive response or an event requiring care. Possible pregnancy, breastfeeding, medical history and treatments must be reported to the team. A list of precautions is not enough to decide on your own whether treatment is suitable.
During treatment, abdominal pain or swelling, weight gain, vomiting, breathing difficulties or reduced urine output require immediate medical contact, according to the LUTRELEF package leaflet. Significant breathing difficulties or feeling severely unwell require contacting emergency services, on 15 or 112 in France.
The diagnostic SmPC for LHRH FERRING also describes a risk of bleeding or ischaemia in the presence of a pituitary adenoma. A sudden headache with visual disturbance requires urgent assessment, not an improvised treatment adjustment.
Medicine versus research vial: the right checklist
The question is not just “is the molecule pure?” You need to establish the product’s identity and the framework in which its quality and use have been assessed. The word research does none of these checks for you.
This checklist helps identify the gap:
| Point to establish | Identifiable human medicine | Vial presented as a research product |
|---|---|---|
| Regulatory identity | Verifiable product name and authorisation | A peptide name or chemical number does not demonstrate a marketing authorisation |
| Intended use | Indication and population described in the SmPC | Laboratory use does not demonstrate suitability for human use |
| Quality | Pharmaceutical requirements attached to the authorised product | A claimed purity is not enough to document all checks |
| Use | Prescription, package leaflet, monitoring and pharmacovigilance | A sales sheet does not provide a validated therapeutic framework |
| Interchangeability | To be established within the appropriate pharmaceutical framework | No substitution for LUTRELEF can be inferred from the label |
A chemical analysis does not answer every question: batch identity, quantity actually delivered, sterility and endotoxins are separate criteria. I am not concluding that every vial is contaminated. I am concluding that a purity document is not enough to establish its equivalence to an injectable medicine. This checklist is a verification method, not a list that makes self-injection acceptable.
Status in France, verified on 13 October 2026
The Public Medicines Database shows a valid marketing authorisation and List I status for LUTRELEF and LHRH FERRING. The displayed LUTRELEF SmPC is dated 2 September 2019, and the LHRH FERRING SmPC is dated 10 September 2018. The date on which sources were consulted for this article should not be confused with these document dates.
The ANMV index lists Cystoreline as having a French veterinary marketing authorisation and prescription-only dispensing status. These listings establish regulatory status, not immediate stock availability. For a prescription, the team and pharmacist check actual supply.
The DGCCRF, in its factsheet dated 7 April 2026, notes that online sales of prescription-only medicines are prohibited in France. Describing a product as “for research” proves neither a human marketing authorisation nor authorisation for therapeutic use. The legal classification of a given product depends on its characteristics and presentation: the word gonadorelin alone is not enough to determine the status of every product.
Questions to ask your specialist
If a prescription or assessment mentions gonadorelin, bring the exact product name, your treatments and any results already available. You can prepare these questions:
- What diagnosis are we trying to confirm or treat?
- Is this a pituitary response test or a fertility treatment?
- Why are this medication and formulation right for my case?
- Which outcomes will be monitored, and who is responsible for monitoring them?
- Which symptoms mean I should call the team immediately?
- What are the instructions if pregnancy is possible or if there is a problem with the device?
- Which alternatives fit the diagnosis and fertility goals?
The specialist can answer questions about your case. An editorial table can only help you formulate those questions. If you have already used a non-prescribed product, tell your healthcare professional its name, where it came from and when you used it. Do not try to counteract its effects on your own with a second peptide.
The Verdict
Main sources
The official documents and human data used are as follows:
